1. Home
  2. MDWD vs EVC Comparison

MDWD vs EVC Comparison

Compare MDWD & EVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • EVC
  • Stock Information
  • Founded
  • MDWD 2000
  • EVC 1996
  • Country
  • MDWD Israel
  • EVC United States
  • Employees
  • MDWD N/A
  • EVC N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • EVC Broadcasting
  • Sector
  • MDWD Health Care
  • EVC Industrials
  • Exchange
  • MDWD Nasdaq
  • EVC Nasdaq
  • Market Cap
  • MDWD 184.8M
  • EVC 155.7M
  • IPO Year
  • MDWD 2014
  • EVC 2000
  • Fundamental
  • Price
  • MDWD $18.23
  • EVC $1.92
  • Analyst Decision
  • MDWD Strong Buy
  • EVC
  • Analyst Count
  • MDWD 2
  • EVC 0
  • Target Price
  • MDWD $32.00
  • EVC N/A
  • AVG Volume (30 Days)
  • MDWD 65.1K
  • EVC 438.6K
  • Earning Date
  • MDWD 03-19-2025
  • EVC 03-06-2025
  • Dividend Yield
  • MDWD N/A
  • EVC 10.18%
  • EPS Growth
  • MDWD N/A
  • EVC N/A
  • EPS
  • MDWD N/A
  • EVC N/A
  • Revenue
  • MDWD $19,720,000.00
  • EVC $364,948,000.00
  • Revenue This Year
  • MDWD $10.15
  • EVC N/A
  • Revenue Next Year
  • MDWD $25.62
  • EVC N/A
  • P/E Ratio
  • MDWD N/A
  • EVC N/A
  • Revenue Growth
  • MDWD N/A
  • EVC 22.86
  • 52 Week Low
  • MDWD $12.78
  • EVC $1.33
  • 52 Week High
  • MDWD $24.00
  • EVC $2.73
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 55.16
  • EVC 41.88
  • Support Level
  • MDWD $16.00
  • EVC $1.77
  • Resistance Level
  • MDWD $18.29
  • EVC $2.15
  • Average True Range (ATR)
  • MDWD 1.00
  • EVC 0.15
  • MACD
  • MDWD 0.16
  • EVC -0.02
  • Stochastic Oscillator
  • MDWD 75.24
  • EVC 45.89

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About EVC Entravision Communications Corporation

Entravision Communications Corp is a global advertising solutions, media, and technology company. Its operations encompass integrated marketing and media solutions, comprised of television, radio, and digital properties and data analytics services. The company operates in television broadcasting, audio broadcasting, and digital media segments. The Company's digital segment, whose operations are located in Europe, Latin America, Asia, the United States, and Africa. The Company's television and audio operations reach and engage U.S. Hispanics in the United States.

Share on Social Networks: